Business Context and Reporting Period
This Form 8-K is a current report filed by AgeX Therapeutics, Inc. (not Serina Therapeutics, Inc.) on July 23, 2021. The registrant is a Delaware corporation with principal executive offices in Alameda, California, and its common stock trades on the NYSE American under the symbol AGE. The company identifies itself as an emerging growth company.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report serves solely to announce a corporate event and does not contain financial statements or performance data.
Material Changes
The report discloses no material changes to financial position or operations. The sole event reported is the issuance of a press release on July 23, 2021, which is incorporated by reference as Exhibit 99.1.
Guidance, Outlook, and Risks
The filing includes a standard forward-looking statements disclaimer. It warns that statements containing words such as "may," "will," "believes," or "expects" are subject to risks and uncertainties. The company directs investors to the "Risk Factors" section of its periodic reports for details on factors that could cause actual results to differ materially from anticipated results. No specific guidance or management commentary regarding future performance is included in this text.
Key Facts for Investor Verification
- Verify the content of the press release filed as Exhibit 99.1, as the 8-K itself only references this document for details on the reported event.
- Confirm the company name is AgeX Therapeutics, Inc., as the input metadata incorrectly listed "Serina Therapeutics, Inc."
- Note that the company is classified as an emerging growth company and has elected not to use the extended transition period for new accounting standards.
- Review the company's most recent periodic reports (10-K or 10-Q) for actual financial metrics, as none are provided in this filing.